middle.news
Amplia Advances Narmafotinib Trials and Board with $24M Cash Position
8:29am on Wednesday 29th of July, 2026 AEST
•
Pharmaceuticals
Read Story
Amplia Advances Narmafotinib Trials and Board with $24M Cash Position
8:29am on Wednesday 29th of July, 2026 AEST
Key Points
ACCENT trial shows improved survival and response rates
Phase 2b pancreatic cancer study to test daily dosing starts Q4 2026
PRROSE trial launched for ovarian cancer with ANZGOG partnership
Board renewal with Jane Bell as Chair and Brett Carter appointed
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE